Dr. Luc Vallières is a Professor in the Department of Molecular Medicine at Laval University and a neuroimmunology researcher in the Neuroscience Unit at the CHU de Québec.

He began his career in 2002 after a postdoctoral training at the Salk Institute in California in the field of postnatal neurogenesis (1998-2001). This training was preceded by a doctorate in physiology at Laval University (1993-1998) and a bachelor’s degree in biology at the Université du Québec à Chicoutimi (1990-1993).

He is studying two diseases that afflict the central nervous system: multiple sclerosis and brain cancer. His research program aims to better understand how immune cells are regulated in these diseases in the hope of finding a way to neutralize or stimulate them for therapeutic purposes. This program is well funded by the CIHR, NSERC and Multiple Sclerosis Society of Canada.

He has made a significant contribution to the field of neuroimmunology by discovering a population of immune cells that constantly patrols the blood vessels of the nervous system and by elucidating mechanisms that govern their recruitment and functions under inflammatory conditions.

His research led to an international patent claiming the first ever drug that would specifically calm the neutrophil, an immune cell normally beneficial, but that can be involved in many inflammatory diseases.

His technical background includes single cell-RNA sequencing, STED super-resolution microscopy, flow cytometry, CRISPR-Cas9 gene editing and RNA interference, as well as bone marrow transplantation. Strong of this expertise, he directs the super-resolution microscopy and irradiation platforms at the CHU de Québec.

He is responsible of two courses, namely Principles of Neuroimmunology (MMO-7010) and Current Techniques in Molecular Medicine (MMO-7019).

Among his external activities, he is chairing the organizing committee of the 16th Congress of the International Society of Neuroimmunology, which will take place in Quebec City in August 2022. He is associate editor of the journal Mediators of Inflammation. He also serves on neuroscience committees at the CIHR.

CHUL
2705, boulevard Laurier
T2-41
Québec, Québec
Canada G1V 4G2
44 entries « 1 of 5 »

Morin F, Singh N, Mdzomba JB, Dumas A, Patenaude A, Pernet V, Vallières L

Correction: Conditional Deletions of Hdc Confirm Roles of Histamine in Anaphylaxis and Circadian Activity but Not in Autoimmune Encephalomyelitis

Journal Article

J Immunol, 2023.

Abstract | Links:

St-Pierre MK, Carrier M, González Ibáñez F, Šimončičová E, Wallman MJ, Vallières L, Parent M, Tremblay MÈ

Ultrastructural characterization of dark microglia during aging in a mouse model of Alzheimer's disease pathology and in human post-mortem brain samples

Journal Article

J Neuroinflammation, 19 (1), 2022.

Abstract | Links:

Uyar O, Dominguez JM, Bordeleau M, Lapeyre L, Ibáñez FG, Vallières L, Tremblay ME, Corbeil J, Boivin G

Single-cell transcriptomics of the ventral posterolateral nucleus-enriched thalamic regions from HSV-1-infected mice reveal a novel microglia/microglia-like transcriptional response

Journal Article

J Neuroinflammation, 19 (1), 2022.

Abstract | Links:

Bérard M, Sheta R, Malvaut S, Rodriguez-Aller R, Teixeira M, Idi W, Turmel R, Alpaugh M, Dubois M, Dahmene M, Salesse C, Lamontagne-Proulx J, St-Pierre MK, Tavassoly O, Luo W, Del Cid-Pellitero E, Qazi R, Jeong JW, Durcan TM, Vallières L, Tremblay ME, Soulet D, Lévesque M, Cicchetti F, Fon EA, Saghatelyan A, Oueslati A

A light-inducible protein clustering system for in vivo analysis of α-synuclein aggregation in Parkinson disease

Journal Article

PLoS Biol, 20 (3), 2022.

Abstract | Links:

Joly S, Mdzomba JB, Rodriguez L, Morin F, Vallières L, Pernet V

B cell-dependent EAE induces visual deficits in the mouse with similarities to human autoimmune demyelinating diseases

Journal Article

J Neuroinflammation, 19 (1), 2022.

Abstract | Links:

Salem M, Lecka J, Pelletier J, Gomes Marconato D, Dumas A, Vallières L, Brochu G, Robaye B, Jobin C, Sévigny J

NTPDase8 protects mice from intestinal inflammation by limiting P2Y6 receptor activation: identification of a new pathway of inflammation for the potential treatment of IBD

Journal Article

Gut, 71 (1), 2022.

Abstract | Links:

Touati S, Djekkoun R, Vallières L, Raymond V, Chabi A, Abadi N, Satta D

Glioma genetic susceptibility and survival analysis in the East Algerian population

Journal Article

The African journal of neurological sciences : official organ of the Pan African Association of Neurological Sciences, 40 (1), 2021.

| Links:

Morin F, Singh N, Mdzomba JB, Dumas A, Pernet V, Vallières L

Conditional Deletions of Hdc Confirm Roles of Histamine in Anaphylaxis and Circadian Activity but Not in Autoimmune Encephalomyelitis

Journal Article

J Immunol, 206 (9), 2021.

Abstract | Links:

El Hajj H, Savage JC, Bisht K, Parent M, Vallieres L, Rivest S, Tremblay ME

Ultrastructural evidence of microglial heterogeneity in Alzheimer's disease amyloid pathology

Journal Article

J Neuroinflammation, 16 (1), 2019.

Abstract | Links:

Morquette B, Juzwik CA, Drake SS, Charabati M, Zhang Y, Lecuyer MA, Galloway DA, Dumas A, de Faria Junior O, Paradis-Isler N, Bueno M, Rambaldi I, Zandee S, Moore C, Bar-Or A, Vallieres L, Prat A, Fournier AE

MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis

Journal Article

Brain, 142 (10), 2019.

Abstract | Links:

44 entries « 1 of 5 »
Signaler des ajouts ou des modifications

Active projects

  • Autoantibodies and antibody-producing cells in neurological autoimmune diseases: from biology to therapeutic targeting, from 2023-10-01 to 2028-09-30
  • Dual function of autoantibodies in a model of multiple sclerosis, from 2023-03-01 to 2024-02-29
  • endMS National Education and Training Program: Summer School and SPRINT, from 2023-06-15 to 2026-06-14
  • Mécanisme d’action d’ASPRV1 dans l’inflammation, from 2021-04-01 to 2026-03-31

Recently finished projects

  • 16th Congress of the International Society of Neuroimmunology (ISNI 2023), from 2022-06-01 to 2023-05-31
  • Characterization of a novel dendritic cell-specific protein in demyelinating autoimmune diseases, from 2019-04-01 to 2022-03-31
  • Plate-forme de production de nanoparticules lipidiques pour le développement de thérapies à base d'acides nucléiques, from 2022-03-22 to 2023-09-28
  • Suppression of regulatory B cells by neutrophils in a model of multiple sclerosis, from 2018-10-01 to 2023-03-31
Data provided by the Université Laval research projects registery